Friday, April 15, 2016 2:27:32 PM
Basically they are limping along, the class a shareholders are reaping huge (useless) share dividends, revenue is stale. The only hope is renewed vision and management but who knows where that will come from.
The revenue seems somewhat stable, they've been forced to cut costs after Raefield but that's not what I was here for, a .01 stock and stable sales.
A few things I noticed:
Revenue. 2014 revenue was $4.1 M US. 2015 Revenue was $4.8M US. The company announced a $2M software agreement with the US Government over 2 years. The first software was $800K so it appears that the operational company sales actually shrank a bit.
Marketing expenses down 22%. This is just part of the insanity. The company spends years developing nexgen technology and then decides not to market it.
R&D - company plans to reduce R&D.
It's just me but maybe the company should be spending money on marketing and R&D not executive pay and foolishness.
Executive compensation. Sieracki is getting payed over $200K to drive a $4M company into the ground. Sad
Lawsuit. Viscount was suing the ex-CEO for all kinds of alleged misfeasance and somehow settled by paying him 3M options and 3M warrants. Sounds like they didn't have much of a case omg.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM